Press release | LabGenius Appoints Dr. Hannah Seitz as Chief Business Officer

LONDON, United Kingdom — 09/01/25 LabGenius, a drug discovery company pioneering the use of machine learning (ML) and high-throughput experimentation to discover novel therapeutic antibodies, including those with complex multispecific designs, today announced the appointment of Hannah Seitz Ph.D. as Chief Business Officer (CBO).

LabGenius’ unique discovery capability is powered by EVA™: a smart robotic platform capable of designing, conducting and, critically, learning from its own experiments. For its wholly-owned pipeline of T-cell engagers and antibody-drug conjugates, the company is using its platform to address the challenge of on-target, off-tumour toxicity. As CBO, Hannah will leverage her extensive expertise in business development and oncology to establish strategic partnerships with biotechnology and pharmaceutical companies who wish to gain access to the company’s cutting-edge platform to enhance their discovery pipelines. 

“We’re delighted that Hannah has joined the team,” said Dr. James Field, CEO of LabGenius. “Her extensive experience in sourcing and executing deals, combined with our proven ability to discover high-performing molecules with non-intuitive designs, will be instrumental in the success of our partnerships.” 

Hannah joins LabGenius from drug discovery and development company Evotec, where she served as VP Global Business Development for Oncology, Immunology and Inflammation. In this role, she led the global out-licensing efforts across internal R&D assets and technology platforms, playing a pivotal part in securing a multi-year collaboration and license agreement with Pfizer. Prior to Evotec, Hannah spent over a decade as Director of Business Development at Daiichi Sankyo, focusing on in-licensing for oncology and rare diseases. During this time, she contributed to numerous early- and late-stage licensing agreements and M&A activities. 

Commenting on her appointment, Dr. Hannah Seitz said, “The team at LabGenius has built an innovative closed-loop technology platform that enables the functional evaluation of vast numbers of antibody designs, including complex multispecific molecules. I look forward to applying my experience to help future partners unlock the potential of these next-generation antibodies.”